Payment overview · 2025
General Payments
$339.85
18 reported records · 7 companies
Healthcare provider profile · identity verified
Meri Kryss, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PHILADELPHIA, PA · NPI 1750499471
Verified facts
What the public records show
CMS Open Payments records show Meri Kryss, MD received $339.85 in general payments during 2025 across 18 reported records.
ABBVIE INC. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Linzess, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 290 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Zenpep by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $111.85 | 32.9% | 6 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.25 | 16.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $50.96 | 15.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $47.46 | 14.0% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $30.10 | 8.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.00 | 7.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.23 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $339.85 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $111.85 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $111.85 | 6 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $55.25 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $50.96 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $47.46 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $30.10 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 120 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 290 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 254 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
120 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
290 | 36 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
122 | 11 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
254 | 27 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 894 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 735 | 92 |
| Vascepa | Icosapent Ethyl | 674 | 77 |
| Montelukast Sodium | Montelukast Sodium | 635 | 77 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 614 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 609 | 73 |
| Citalopram Hbr | Citalopram Hydrobromide | 477 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 456 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 430 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 357 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 352 | 58 |
| Donepezil Hcl | Donepezil Hcl | 350 | 37 |
| Doxazosin Mesylate | Doxazosin Mesylate | 323 | 36 |
| Losartan Potassium | Losartan Potassium | 306 | 36 |
| Omeprazole | Omeprazole | 299 | 37 |
| Linzess | Linaclotide | 290 | 36 |
| Myrbetriq | Mirabegron | 283 | 34 |
| Metformin Hcl | Metformin Hcl | 266 | 32 |
| Eliquis | Apixaban | 258 | 32 |
| Zenpep | Lipase/Protease/Amylase | 254 | 27 |
| Furosemide | Furosemide | 246 | 32 |
| Gabapentin | Gabapentin | 233 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 231 | 42 |
| Valsartan | Valsartan | 224 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 26 |
| Alprazolam | Alprazolam | 218 | 21 |
| Azelastine Hcl | Azelastine Hcl | 216 | 78 |
| Clonidine Hcl | Clonidine Hcl | 214 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 189 | 26 |
| Ranolazine Er | Ranolazine | 185 | 19 |
| Potassium Chloride | Potassium Chloride | 182 | 25 |
| Dexlansoprazole Dr | Dexlansoprazole | 176 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 23 |
| Lisinopril | Lisinopril | 165 | 22 |
| Memantine Hcl Er | Memantine Hcl | 156 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 155 | 17 |
| Meclizine Hcl | Meclizine Hcl | 151 | 25 |
| Lidocaine | Lidocaine | 147 | 17 |
| Famotidine | Famotidine | 146 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 145 | 30 |
| Atenolol | Atenolol | 144 | 16 |
| Memantine Hcl | Memantine Hcl | 132 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 130 | 15 |
| Azithromycin | Azithromycin | 128 | 99 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 123 | 77 |
| Synthroid | Levothyroxine Sodium | 122 | 11 |
| Tradjenta | Linagliptin | 121 | 15 |
| Creon | Lipase/Protease/Amylase | 120 | 15 |
| Ezetimibe | Ezetimibe | 120 | 16 |
| Allopurinol | Allopurinol | 115 | 14 |
| Meloxicam | Meloxicam | 115 | 25 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 112 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 111 | 12 |
| Carvedilol | Carvedilol | 104 | 13 |
| Simvastatin | Simvastatin | 99 | 15 |
| Methylprednisolone | Methylprednisolone | 96 | 74 |
| Trazodone Hcl | Trazodone Hcl | 93 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 17 |
| Alendronate Sodium | Alendronate Sodium | 89 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | suppressed |
| Ketoconazole | Ketoconazole | 86 | 14 |
| Ammonium Lactate | Ammonium Lactate | 85 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 15 |
| Sertraline Hcl | Sertraline Hcl | 82 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | suppressed |
| Mirtazapine | Mirtazapine | 79 | suppressed |
| Glimepiride | Glimepiride | 78 | 11 |
| Clonazepam | Clonazepam | 77 | suppressed |
| Procto-Med Hc | Hydrocortisone | 76 | 13 |
| Tramadol Hcl | Tramadol Hcl | 74 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | suppressed |
| Celecoxib | Celecoxib | 68 | 12 |
| Nitroglycerin | Nitroglycerin | 68 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 63 | suppressed |
| Clotrimazole | Clotrimazole | 61 | suppressed |
| Glipizide | Glipizide | 57 | suppressed |
| Hydrocortisone | Hydrocortisone | 56 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 56 | suppressed |
| Sotalol | Sotalol Hcl | 56 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 49 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 11 |
| Finasteride | Finasteride | 47 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Lansoprazole | Lansoprazole | 43 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 42 | suppressed |
| Gemtesa | Vibegron | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | suppressed |
| Mupirocin | Mupirocin | 41 | 12 |
| Colchicine | Colchicine | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Proctozone-Hc | Hydrocortisone | 35 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Dexilant | Dexlansoprazole | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Restasis | Cyclosporine | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Loperamide | Loperamide Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Lumigan | Bimatoprost | 25 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Ursodiol | Ursodiol | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 16 | suppressed |
| Ultra Comfort | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Diovan | Valsartan | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Rhopressa | Netarsudil Mesylate | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Singulair | Montelukast Sodium | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Cardura Xl | Doxazosin Mesylate | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
| Rectiv | Nitroglycerin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $339.85 · 18 records | ABBVIE INC. | CREON, GEMTESA, IBSRELA, LINZESS, REXULTI, VOQUEZNA, ZENPEP, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error